---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References"
description: "Reference list for the formulary evidence report on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria. 177 cited documents."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References

<a id="references"></a>

## 5 References

1. [AAAAI Choosing Wisely list](https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Media/Choosing-WiselyT.pdf)
2. [AAAAI Urticaria Measures Set (2015)](https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Practice%20Management/Practice%20Tools/Urticaria-Measures-Set_Final-2015_2026-7-20.pdf)
3. [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)
4. [Abdalla et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13425259/)
5. [ACAAI JTF chronic urticaria guideline announcement (2026)](https://college.acaai.org/new-chronic-urticaria-practice-parameter-update-puts-greater-emphasis-on-core-concepts-patient-centered-implementation/)
6. [Agache et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32767573/)
7. [Altayf et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42714921/)
8. [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)
9. [Alvarado et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12862557/)
10. [Balachandar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13301777/)
11. [Balp et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6084337/)
12. [Balp et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29679413/)
13. [Balp et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8776966/)
14. [Balp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11971071/)
15. [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)
16. [Bernstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180992/)
17. [Broder et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4529877/)
18. [Celldex AAAAI 2026 data release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-additional-positive-data-phase-2-chronic)
19. [Celldex AAD 2026 quality of life release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-positive-data-phase-2-chronic-spontaneous)
20. [Celldex EAACI 2023 urticaria release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab)
21. [Celldex EAACI 2026 angioedema release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-long-term-barzolvolimab-results-demonstrating)
22. [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)
23. [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)
24. [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)
25. [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)
26. [Celldex first quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-first-quarter-financial-results-and-provides)
27. [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)
28. [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)
29. [Celldex fourth quarter 2021 results release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-full-year-2021-financial)
30. [Celldex fourth quarter 2025 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-year-end-2025-financial)
31. [Celldex phase 1b CSU AAAAI release (2023)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-data-barzolvolimab-0)
32. [Celldex phase 1b CSU EAACI release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-positive-interim-data)
33. [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)
34. [Celldex phase 2 CSU 52-week results release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-landmark-52-week-results)
35. [Celldex phase 2 CSU angioedema release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-presents-data-demonstrating-profound)
36. [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)
37. [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)
38. [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)
39. [Celldex second quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-financial-results-and-provides)
40. [Celldex subcutaneous formulation study release (2021)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-initiation-cdx-0159-subcutaneous-formulation)
41. [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)
42. [Chansakulporn et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25023899/)
43. [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)
44. [Chu et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/41060663/)
45. [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)
46. [Chung et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7992631/)
47. [Church et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29431202/)
48. [ClinicalTrials.gov NCT04146129](https://clinicaltrials.gov/study/NCT04146129)
49. [ClinicalTrials.gov NCT04538794](https://clinicaltrials.gov/study/NCT04538794)
50. [ClinicalTrials.gov NCT05031624](https://clinicaltrials.gov/study/NCT05031624)
51. [ClinicalTrials.gov NCT05368285](https://clinicaltrials.gov/study/NCT05368285)
52. [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)
53. [ClinicalTrials.gov NCT06445023 record history](https://clinicaltrials.gov/study/NCT06445023?tab=history&a=1&b=18)
54. [ClinicalTrials.gov NCT06455202](https://clinicaltrials.gov/study/NCT06455202)
55. [ClinicalTrials.gov NCT06455202 record history](https://clinicaltrials.gov/study/NCT06455202?tab=history&a=1&b=18)
56. [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)
57. [Confino-Cohen et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22336078/)
58. [DeLong et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18209166/)
59. [Doğan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42886609/)
60. [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)
61. [Ertas et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29083482/)
62. [Eun et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29945815/)
63. [Fijen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10472988/)
64. [Fok et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33539587/)
65. [Fricke et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31494963/)
66. [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)
67. [Genentech Xolair cost page (2026)](https://www.xolair.com/cost.html)
68. [Gericke et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27838346/)
69. [Giménez-Arnau et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12019677/)
70. [Giménez-Arnau et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41115533/)
71. [Giménez-Arnau et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42242425/)
72. [Gonçalo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32956489/)
73. [Graham et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4929169/)
74. [Guillén-Aguinaga et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27237730/)
75. [Hawro et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29128337/)
76. [Healio (2026)](https://www.healio.com/news/allergy-asthma/20261020/xolair-biosimilar-omlyclo-commercially-available-in-us)
77. [Hu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42697278/)
78. [Huang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12285021/)
79. [Jahn et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729876/)
80. [Jang and Lee (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-3-3/cost-effectiveness-of-remibrutinib-for-moderate-to-severe-chronic-spontaneous-urticaria-in-the-u-s)
81. [Jang et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40955168/)
82. [Kanters et al. (2018)](https://doi.org/10.1111/bjd.16476)
83. [Kaplan et al. (2013)](https://doi.org/10.1016/j.jaci.2013.05.013)
84. [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8724829/)
85. [Kocatürk et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12723574/)
86. [Kocatürk et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41913980/)
87. [Kolkhir et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/28407273/)
88. [Kolkhir et al. (2017b)](https://pubmed.ncbi.nlm.nih.gov/29037900/)
89. [Kolkhir et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34363991/)
90. [Kolkhir et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34611316/)
91. [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)
92. [Kolkhir et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/36109590/)
93. [Kolkhir et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36481420/)
94. [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)
95. [Kolkhir et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466147/)
96. [Konstantinou and Konstantinou (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6706894/)
97. [Kulthanan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916431/)
98. [Kulthanan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658402/)
99. [Lapi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26872037/)
100. [Lapi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702025/)
101. [Mathias et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22192960/)
102. [Maurer et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23432142/)
103. [Maurer et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5724512/)
104. [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/)
105. [Maurer et al. (2023a)](https://celldex.com/wp-content/uploads/2025/06/Safety-and-Clinical-Activity-of-Multiple-Doses-of-Barzolvolimab-an-anti-KIT-Antibody-in-Patients-with-Chronic-Spontaneous-Urticaria.pdf)
106. [Maurer et al. (2023b)](https://celldex.com/wp-content/uploads/2025/06/EAACI2023_CSU_Jun2023_Final.pdf)
107. [Maurer et al. (2023c)](https://celldex.com/wp-content/uploads/2025/06/EADV2023_Patients-With-Chronic-Spontaneous-Urticaria-Experience-Improvement-in-Quality-of-Life-When-Treated-With-Barzolvolimab-1.pdf)
108. [Maurer et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38008109/)
109. [Maurer et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38431226/)
110. [Maurer et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11393262/)
111. [Maurer et al. (2024d)](https://celldex.com/wp-content/uploads/2025/06/CLDX_EADV2024_Congress_Presentation.pdf)
112. [Maurer et al. (2024e)](https://celldex.com/wp-content/uploads/2025/06/Barzolvolimab_Phase-2-ClndU_ACAAI_FINAL.pdf)
113. [Maurer et al. (2025a)](https://doi.org/10.1016/j.jaci.2024.12.985)
114. [Maurer et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368744/)
115. [Metz et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37605867/)
116. [Metz et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40043237/)
117. [Metz et al. (2025b)](https://celldex.com/wp-content/uploads/2025/06/EAACI_Congress_2025-Barzolvolimab-76-Week-LB-FINAL_6.13.25.pdf)
118. [Metz et al. (2025c)](https://celldex.com/wp-content/uploads/2025/06/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf)
119. [Metz et al. (2025d)](https://doi.org/10.1016/j.jaad.2025.08.022)
120. [Metz et al. (2025e)](https://celldex.com/wp-content/uploads/2025/09/EADV2025_Poster.pdf)
121. [Metz et al. (2025f)](https://www.annallergy.org/article/S1081-1206%2825%2900523-X/fulltext)
122. [Metz et al. (2026a)](https://doi.org/10.1016/j.jaci.2026.02.018)
123. [Metz et al. (2026b)](https://celldex.com/wp-content/uploads/2026/02/Barzol_AAAAI-CSU-OT-Analysis-2.27.26.pdf)
124. [Metz et al. (2026c)](https://celldex.com/wp-content/uploads/2026/06/EAACI-2026-Angioedema-Flash-Talk-and-Slides.pdf)
125. [Metz et al. (2026d)](https://celldex.com/wp-content/uploads/2026/10/FCD-2026_Pigmentation-Changes-Poster_FINAL.pdf)
126. [Metz et al. (2026e)](https://celldex.com/wp-content/uploads/2026/11/ACAAI-2026-CSU-P2-High-Low-Tryptase-ePoster_R098.pdf)
127. [Moñino-Romero et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37286132/)
128. [Moñino-Romero et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439351/)
129. [Mosnaim et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12814061/)
130. [Mosnaim et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12990347/)
131. [Mosnaim et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42297099/)
132. [Mtibaa et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-3-4/impact-of-remibrutinib-treatment-on-workplace-productivity-due-to-chronic-spontaneous-urticaria-csu--a-canadian-private-payor-perspective)
133. [Muñoz et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41532284/)
134. [Muñoz et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42206950/)
135. [NICE remibrutinib draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11416/documents/draft-guidance)
136. [NICE TA339 (2015)](https://www.nice.org.uk/guidance/ta339/resources/omalizumab-for-previously-treated-chronic-spontaneous-urticaria-pdf-82602555773893)
137. [Novartis Rhapsido savings and support page (2026)](https://www.rhapsido.com/savings-support)
138. [O'Donnell et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9068731/)
139. [Ocadiz-Ruiz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13755836/)
140. [Ohanyan et al. (2017)](https://doi.org/10.1016/j.jaci.2017.04.050)
141. [Omlyclo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761399s004lbl.pdf)
142. [Oregon PDAB Xolair affordability review (2026)](https://dfr.oregon.gov/pdab/Documents/Xolair-2026.pdf)
143. [Regeneron Dupixent Colorado price disclosure (2026)](https://www.regeneron.com/downloads/codrugcosteducation_dupixent.pdf)
144. [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)
145. [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)
146. [Riedl et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43003384/)
147. [Ryan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9533216/)
148. [Saini et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4269803/)
149. [Saini et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12368742/)
150. [Schoepke et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31228881/)
151. [Shaker et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31751758/)
152. [Soong et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40556432/)
153. [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)
154. [Stull et al. (2017)](https://doi.org/10.1111/bjd.15454)
155. [Sussman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6055840/)
156. [Tan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333250/)
157. [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)
158. [Tharp et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439579/)
159. [Tsai et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177781/)
160. [Viegas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12619656/)
161. [Weller et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23919330/)
162. [Weller et al. (2014)](https://doi.org/10.1016/j.jaci.2013.12.1076)
163. [Weller et al. (2020a)](https://pubmed.ncbi.nlm.nih.gov/31815297/)
164. [Weller et al. (2020b)](https://pubmed.ncbi.nlm.nih.gov/32173507/)
165. [Weller et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909366/)
166. [Weller et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12454223/)
167. [Wertenteil et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30872154/)
168. [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)
169. [Williams et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5825330/)
170. [Williams et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29514728/)
171. [Xiong et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41186128/)
172. [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)
173. [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)
174. [Yücel and Ünal (2026)](https://pubmed.ncbi.nlm.nih.gov/43019004/)
175. [Zhao et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12053928/)
176. [Zuberbier et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456386/)
177. [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
